What is 4D Molecular Therapeutics's financing cash flow?

4D Molecular Therapeutics (FDMT) reported financing cash flow of $11.48M in Q1 2026.

What is the long-term trend for 4D Molecular Therapeutics's financing cash flow?

Over 4 years (2021 to 2025), 4D Molecular Therapeutics's financing cash flow has grown at a -1.1% compound annual growth rate (CAGR), from $118.09M to $112.96M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

4D Molecular Therapeutics FDMT Financing Cash Flow

Financing Cash Flow at other companies

Eli LillyLLY

-$3.47B-351%

Regeneron PharmaceuticalsREGN

-$802.2M+26.3%

Vertex PharmaceuticalsVRTX

-$538.8M+20.8%

EyePoint, Inc. EYPT

-$2.61M-175%

AbbVieABBV

$919M+173%

RegenxbioRGNX

-$13.64M-135%

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's financing cash flow?: 4D Molecular Therapeutics (FDMT) reported financing cash flow of $11.48M in Q1 2026.
What is the long-term trend for 4D Molecular Therapeutics's financing cash flow?: Over 4 years (2021 to 2025), 4D Molecular Therapeutics's financing cash flow has grown at a -1.1% compound annual growth rate (CAGR), from $118.09M to $112.96M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.